A treatment regimen combining a front-line chemotherapeutic like cisplatin with a TLS inhibitor would not only increase cancer cell chemosensitivity but also decrease chemotherapeutic resistance, reducing cancer recurrence and secondary malignancies, therefore improving patient outcomes. The gene discussed is FUS; the disease is cancer.